Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) or programmed death-ligand 1 (PD-L1) have revolutionised treatment approaches of several cancers, including non-small cell lung cancer (NSCLC) [1–5]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.